| Authors: |
Rayens E; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Sy LS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Qian L; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Ackerson BK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., An J; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Luo Y; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Huang X; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Ku JH; Center for Integrated Health Care Research, Kaiser Permanente, Honolulu, Hawaii, USA., Modha PP; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Bathala RM; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Venkatesan S; BPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom., Glasser L; Vaccines and Immune Therapies, AstraZeneca, Wilmington, Delaware, USA., Molnar D; Vaccines and Immune Therapies, AstraZeneca, Barcelona, Spain., McNulty R; Vaccines and Immune Therapies, AstraZeneca, Cambridge, United Kingdom., Wang C; Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, Maryland, USA., Tseng HF; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. |
